Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04919629
Title APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer



Bevacizumab + Pegcetacoplan + Pembrolizumab

Pegcetacoplan + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.